Spark Therapeutics (ONCE) Receiving Somewhat Favorable News Coverage, Report Finds
News coverage about Spark Therapeutics (NASDAQ:ONCE) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spark Therapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4708330213356 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Spark Therapeutics’ (ONCE) “Buy” Rating Reaffirmed at Barclays (americanbankingnews.com)
- Spark Therapeutics Inc to Post Q2 2018 Earnings of ($1.47) Per Share, Leerink Swann Forecasts (ONCE) (americanbankingnews.com)
- Spark Therapeutics’ (ONCE) “Outperform” Rating Reiterated at Sanford C. Bernstein (americanbankingnews.com)
- UBS Loses Conviction In Spark Therapeutics, Downgrades (msn.com)
- Spark Therapeutics: This Looks Bad (finance.yahoo.com)
Several brokerages have recently commented on ONCE. Evercore ISI began coverage on Spark Therapeutics in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 price target on the stock. Chardan Capital decreased their price target on Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating on the stock in a research note on Tuesday. Wedbush raised Spark Therapeutics from an “underperform” rating to a “neutral” rating and decreased their price target for the company from $65.00 to $50.00 in a research note on Tuesday. They noted that the move was a valuation call. Sanford C. Bernstein set a $71.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Finally, Barclays reaffirmed a “buy” rating and issued a $54.00 price target on shares of Spark Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and an average target price of $79.14.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. Spark Therapeutics’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.07) EPS. equities analysts expect that Spark Therapeutics will post -7.6 EPS for the current fiscal year.
In other Spark Therapeutics news, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the sale, the insider now owns 8,146 shares in the company, valued at approximately $581,950.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $84.63, for a total value of $84,630,000.00. Following the sale, the director now owns 3,928,707 shares in the company, valued at approximately $332,486,473.41. The disclosure for this sale can be found here. Insiders sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last quarter. Company insiders own 7.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Spark Therapeutics (ONCE) Receiving Somewhat Favorable News Coverage, Report Finds” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/14/spark-therapeutics-once-receiving-somewhat-favorable-news-coverage-report-finds.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.